Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia.

Autor: McGarry LJ; a a ARIAD Pharmaceuticals Inc. , Cambridge , MA , USA., Chen YJ; b b IMS Health , Fairfax , VA , USA., Divino V; b b IMS Health , Fairfax , VA , USA., Pokras S; b b IMS Health , Fairfax , VA , USA., Taylor CR; a a ARIAD Pharmaceuticals Inc. , Cambridge , MA , USA., Munakata J; b b IMS Health , Fairfax , VA , USA., Nieset CC; a a ARIAD Pharmaceuticals Inc. , Cambridge , MA , USA., Huang H; a a ARIAD Pharmaceuticals Inc. , Cambridge , MA , USA., Jabbour E; c c MD Anderson Cancer Center , Houston , TX , USA., Malone DC; d d University of Arizona College of Pharmacy , Tucson , AZ , USA.

Publikováno v: Current medical research and opinion [Curr Med Res Opin] 2016; Vol. 32 (2), pp. 289-99. Date of Electronic Publication: 2015 Nov 30.